Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIST NASDAQ:SLGL NASDAQ:TLSA NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMISTMilestone Pharmaceuticals$1.48+3.1%$1.69$1.00▼$3.06$183.64M1.042.22 million shs358,140 shsSLGLSol-Gel Technologies$66.10+4.4%$75.41$6.80▼$97.97$185.75M1.1633,207 shs6,101 shsTLSATiziana Life Sciences$1.42+2.9%$1.31$1.14▼$2.60$180.71M0.42188,039 shs30,557 shsXCURExicure$2.96+2.2%$3.86$2.75▼$11.00$18.82M3.6226,414 shs10,419 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMISTMilestone Pharmaceuticals-2.05%-24.74%-31.90%-14.37%+10.85%SLGLSol-Gel Technologies-7.37%-5.80%-14.30%-21.85%+720.08%TLSATiziana Life Sciences+2.22%-11.54%+11.29%-1.43%-6.76%XCURExicure-5.56%-10.80%-23.75%-21.04%-71.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMISTMilestone Pharmaceuticals$1.48+3.1%$1.69$1.00▼$3.06$183.64M1.042.22 million shs358,140 shsSLGLSol-Gel Technologies$66.10+4.4%$75.41$6.80▼$97.97$185.75M1.1633,207 shs6,101 shsTLSATiziana Life Sciences$1.42+2.9%$1.31$1.14▼$2.60$180.71M0.42188,039 shs30,557 shsXCURExicure$2.96+2.2%$3.86$2.75▼$11.00$18.82M3.6226,414 shs10,419 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMISTMilestone Pharmaceuticals-2.05%-24.74%-31.90%-14.37%+10.85%SLGLSol-Gel Technologies-7.37%-5.80%-14.30%-21.85%+720.08%TLSATiziana Life Sciences+2.22%-11.54%+11.29%-1.43%-6.76%XCURExicure-5.56%-10.80%-23.75%-21.04%-71.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMISTMilestone Pharmaceuticals 2.50Moderate Buy$7.25391.53% UpsideSLGLSol-Gel Technologies 2.75Moderate Buy$110.0066.40% UpsideTLSATiziana Life Sciences 1.00SellN/AN/AXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TLSA, XCUR, SLGL, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026SLGLSol-Gel Technologies Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/14/2026MISTMilestone Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$8.00 ➝ $7.005/11/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/10/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$6.004/9/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy2/24/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMISTMilestone Pharmaceuticals$1.55M118.48N/AN/A$0.29 per share5.09SLGLSol-Gel Technologies$19.39M9.58N/AN/A$8.19 per share8.07TLSATiziana Life SciencesN/AN/AN/AN/AN/AN/AXCURExicure$500K37.65N/AN/A$0.62 per share4.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%N/ASLGLSol-Gel Technologies-$6.13M-$2.23N/AN/AN/A-31.60%-24.29%-18.73%5/22/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)XCURExicure-$4.95M-$0.77N/AN/AN/AN/A-138.71%-62.76%8/7/2026 (Estimated)Latest TLSA, XCUR, SLGL, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026SLGLSol-Gel Technologies-$2.86N/AN/AN/A$0.90 millionN/A5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 million5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/25/2026Q4 2025XCURExicure-$18.60-$0.46+$18.14-$0.46$1.64 millionN/A3/20/2026Q4 2025MISTMilestone Pharmaceuticals-$0.18-$0.16+$0.02-$0.15$37.52 million$1.55 million3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMISTMilestone Pharmaceuticals1.619.189.09SLGLSol-Gel TechnologiesN/A4.374.37TLSATiziana Life SciencesN/A0.760.76XCURExicureN/A1.191.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMISTMilestone Pharmaceuticals86.18%SLGLSol-Gel Technologies26.18%TLSATiziana Life SciencesN/AXCURExicure42.82%Insider OwnershipCompanyInsider OwnershipMISTMilestone Pharmaceuticals19.50%SLGLSol-Gel Technologies66.51%TLSATiziana Life Sciences39.82%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMISTMilestone Pharmaceuticals30124.50 million100.22 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataTLSATiziana Life Sciences8127.26 million76.58 millionOptionableXCURExicure506.37 million3.01 millionNot OptionableTLSA, XCUR, SLGL, and MIST HeadlinesRecent News About These CompaniesExicure delays quarterly filing, trims quarterly lossMay 15, 2026 | tipranks.comExicure (XCUR) to Release Earnings on WednesdayMay 11, 2026 | americanbankingnews.comExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comExicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem MeetingsJanuary 21, 2026 | quiverquant.comQExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsJanuary 21, 2026 | globenewswire.comSangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) StockDecember 11, 2025 | insidertrades.comFutures tread cautiously pre-market as investors await key Fed decision: NVDA, XCUR, GME, CASY among stocks to watchDecember 10, 2025 | msn.comThis BlackRock stock just rocketed 70%December 9, 2025 | finbold.comFExicure presents topline data from burixafor combination trialDecember 8, 2025 | msn.comExicure stock soars after positive Phase 2 data for multiple myeloma drugDecember 8, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, XCUR, SLGL, and MIST Company DescriptionsMilestone Pharmaceuticals NASDAQ:MIST$1.48 +0.05 (+3.15%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Sol-Gel Technologies NASDAQ:SLGL$66.10 +2.79 (+4.41%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Tiziana Life Sciences NASDAQ:TLSA$1.42 +0.04 (+2.90%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Exicure NASDAQ:XCUR$2.96 +0.07 (+2.25%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear Arhaus Stock Drops to 52-Week Low After Q1 Earnings Tesla Ends Model S and X Era, Bets Everything on What's Next Why Home Depot’s Sell-Off Could Become a Huge Opportunity Palo Alto Networks Up 70%: Can the Rally Last Into June? Brady Corp Wires Up a Massive AI-Powered Breakout Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
